$CELU News

Celularity Secures $1M Secured Loan From Philip & Daniele Barach Family Trust On June 29, 2026

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Celularity Releases CEO Letter to Shareholders

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity Receives Nasdaq Noncompliance Notice

Celularity Enters Settlement With Helena Global To Restructure Convertible Note Obligations, Including $500K Upfront And $100K Monthly Payments Plus Note Assignment

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation

NEXGEL Appoints Ian Blackman as Chief Financial Officer

NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

Celularity Announces Closing of Transaction with NexGel

NEXGEL, Inc. Q4 2025 Earnings Call Summary

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Celularity Receives Nasdaq Notice Regarding Late Form 10-K Filing

NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction

NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction

NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities